Skip to main content
Premium Trial:

Request an Annual Quote

Budget Sequestration and State-level Losses

The federal budget sequestration plan that is set to be enacted at the start of 2013 will have dramatic effects on National Institutes of Health funding, which is likely to see a 7.8 percent gash to its budget, resulting in less research money to the states and fewer lab jobs, according to United for Medical Research, an advocacy organization that works for enhanced federal support for bioscience.

UMR has issued a report and a new online map that highlight how states would be hurt by the across-the board sequester cuts, officially known as the Budget Control Act, which were created by Congress last year as a way to ensure that the Joint Select Committee on Deficit Reduction reached a deal on cutting the debt.

When that 'Supercommittee' failed to reach a deal, the process was set in motion that will lead to sequester cuts at the beginning of the year unless another deal is reached on the budget or to change them.

National Institutes of Health Director Francis Collins told a US Senate subcommittee earlier this year that the sequester would be "devastating" to NIH, resulting in a cut of $2.4 billion and resulting in around 2,300 fewer grants.

UMR has estimated that the sequester would lead to around 1,900 fewer grants, which in turn would reduce the total employment supported by NIH awards by 33,700 jobs, leading to a loss of around $4.5 billion in economic activity.

A new map posted on UMR's website shows a state-by-state estimate of how the sequester at NIH could impact regional research and economic activities. States that have more biomedical research capacity might see the highest losses, according to UMR. For example, California could lose $275.8 million in grants, resulting in nearly 5,000 fewer jobs; NIH funding to Massachusetts could drop by around $195.6 million, resulting in as many as 2,700 fewer jobs; and North Carolina could see a drop of $82.9 million in NIH funding, affecting 1,605 jobs.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.